These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 36709471)

  • 1. A prognostic cuproptosis-related lncRNA predictive signature for bladder cancer patients.
    Jiang S; Zhang J; Fan Q; Li Z; Dou R; Lin Z; Chen Z; Xu Y; Huang Z; Lan J; Lin W; Xu S; Gao X; Li M
    Hum Cell; 2023 Mar; 36(2):798-811. PubMed ID: 36709471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel cuproptosis-related lncRNA signature predicts the prognosis and immune landscape in bladder cancer.
    Bai Y; Zhang Q; Liu F; Quan J
    Front Immunol; 2022; 13():1027449. PubMed ID: 36451815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of cuproptosis-related long noncoding RNA signature for predicting prognosis and immunotherapy response in bladder cancer.
    Huang G; Huang Y; Zhang C; Jiang Y; Ye Z; He C; Yu F; Chen Z; Xi X
    Sci Rep; 2022 Dec; 12(1):21386. PubMed ID: 36496537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction and validation of cuproptosis-related lncRNA prediction signature for bladder cancer and immune infiltration analysis.
    Li H; Jiang H; Huang Z; Chen Z; Chen N
    Aging (Albany NY); 2023 Aug; 15(16):8325-8344. PubMed ID: 37616061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cuproptosis-related lncRNA signature for prognostic prediction in patients with acute myeloid leukemia.
    Zhu Y; He J; Li Z; Yang W
    BMC Bioinformatics; 2023 Feb; 24(1):37. PubMed ID: 36737692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction of prognostic risk model of bladder cancer based on cuproptosis-related long non-coding RNAs.
    Xu C; Chen A; Mao C; Cui B
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 52(2):139-147. PubMed ID: 37283097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of a prognostic signature for lung adenocarcinoma using cuproptosis-related lncRNAs.
    Yalimaimaiti S; Liang X; Zhao H; Dou H; Liu W; Yang Y; Ning L
    BMC Bioinformatics; 2023 Mar; 24(1):81. PubMed ID: 36879187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction and validation of a cuproptosis-related lncRNA prognosis signature in bladder carcinoma.
    Song J; Sun X; Wang T; Yan L; Su P; Yuan L
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11207-11221. PubMed ID: 37354222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs.
    Zhang X; Ye Z; Xiao G; He T
    Comput Biol Med; 2023 Jun; 159():106905. PubMed ID: 37060773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma.
    Liu Y; Jiang J
    Cancer Biomark; 2023; 37(1):13-26. PubMed ID: 37005878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiosensitization-Related Cuproptosis LncRNA Signature in Non-Small Cell Lung Cancer.
    Xu Q; Liu T; Wang J
    Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36360316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel cuproptosis-related lncRNAs signature predicts prognosis in bladder cancer.
    Wu L; Chen W; Cao Y; Chen B; He Y; Wang X
    Aging (Albany NY); 2023 Jul; 15(13):6445-6466. PubMed ID: 37424068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma.
    Xu M; Mu J; Wang J; Zhou Q; Wang J
    Front Oncol; 2022; 12():961213. PubMed ID: 35965536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma.
    Cheng X; Zeng Z; Yang H; Chen Y; Liu Y; Zhou X; Zhang C; Wang G
    BMC Cancer; 2023 Jan; 23(1):105. PubMed ID: 36717792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive analysis of cuproptosis-related lncRNAs signature to predict prognosis in bladder urothelial carcinoma.
    Zhu S; Li H; Fan Y; Tang C
    BMC Urol; 2023 Jul; 23(1):124. PubMed ID: 37479989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Cuproptosis-Related lncRNAs Signature Could Accurately Predict Prognosis in Patients with Clear Cell Renal Cell Carcinoma.
    Zhang W; Wang H; Wang W; Xue H; Qiao M; Song L; Wang S; Ren Z; Ma Z
    Anal Cell Pathol (Amst); 2022; 2022():4673514. PubMed ID: 36588797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Evaluation of a Novel Cuproptosis-Related lncRNA Signature for Gastric Cancer Prognosis.
    Yin C; Gao M; Wang Q; Li H
    Comput Math Methods Med; 2023; 2023():6354212. PubMed ID: 36820319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma.
    Wang F; Lin H; Su Q; Li C
    World J Surg Oncol; 2022 Sep; 20(1):275. PubMed ID: 36050740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of novel cuproptosis-related lncRNA signatures to predict the prognosis and immune microenvironment of breast cancer patients.
    Jiang ZR; Yang LH; Jin LZ; Yi LM; Bing PP; Zhou J; Yang JS
    Front Oncol; 2022; 12():988680. PubMed ID: 36203428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance and immune landscape of cuproptosis-related lncRNAs in kidney renal clear cell carcinoma: a bioinformatical analysis.
    Li D; Wu X; Song W; Cheng C; Hao L; Zhang W
    Ann Transl Med; 2022 Nov; 10(22):1235. PubMed ID: 36544675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.